Genomics
CRISPR/Cas9 mouse model reveals cellular function changes that drive rare disease
A CRISPR/Cas9 mouse model has shown how mutations that cause a rare disease affect cellular function, shedding light on how to monitor and treat the condition in the process. Read More
At SLAS 2023, companies showcase, launch advanced automation and screening technologies
At the Society for Laboratory Automation and Screening (SLAS) 2023 International Conference and Exhibition, being held in San Diego from February 25 to March 1, numerous firms have announced that they are showcasing emerging technologies for advanced life science applications. Read More
Beckman Coulter, Sciex collaborate on high-throughput screening workflows
Life science analytical technologies company Sciex on Monday announced a collaboration with Beckman Coulter Life Sciences to provide comprehensive workflows for high-throughput screening; high-throughput absorption, distribution, metabolism, and excretion (HT-ADME); and synthetic biology studies. Read More
Algorithm predicts success of next-generation CRISPR edits, advancing push to treat genetic diseases
A machine learning algorithm has predicted the chances of successfully inserting a gene-edited sequence of DNA into a cell using a next-generation CRISPR-Cas9 approach. Read More
Newborn screening for neuromuscular disorder leads to improved outcomes in Australian study
Newborn screening for spinal muscular atrophy (SMA) improves outcomes by enabling timely access to disease-modifying therapy, a prospective study published in the Lancet Child & Adolescent Health found. Read More
T-cell therapy fights viral infections following stem cell transplants
Baylor College of Medicine and Washington University School of Medicine researchers studied posoleucel, an investigational off-the-shelf T-cell therapy that simultaneously targets six different viruses. The results, published January 11 in the journal Clinical Cancer Research, showed promising antiviral efficacy and safety in a phase II clinical trial of patients who had undergone stem cell transplantation to treat blood diseases including cancer. Read More
Discovery of destructive CRISPR enzyme opens diagnostic, therapeutic applications for molecular scissors
The discovery of a CRISPR enzyme that destroys DNA and RNA in target cells has unlocked opportunities to use molecular scissors in diagnostics and to selectively destroy diseased cells. Read More
Cancer-killing vaccine may also prevent brain cancer
Harvard Stem Cell Institute scientists are harnessing a new method of turning cancer cells into potent, anti-cancer agents. Their new cell therapy approach to eliminating established tumors also trains the immune system to prevent cancer from recurring, providing long-term immunity. The NIH-funded study, published January 4 in Science Translational Medicine, showed promising results when the approach was tested on mice with glioblastoma, a deadly brain cancer. Read More
Common genetic cause of late-onset ataxia revealed
A Quebec-led international collaboration has discovered a previously unknown common genetic cause of late-onset cerebellar ataxia. The study, published December 14 in the New England Journal of Medicine, may potentially improve diagnosis and open new treatment avenues for thousands of people with this debilitating neurodegenerative condition worldwide. Read More
CRISPR system targets toxic RNA to improve Huntington's in mice
Genome-editing CRISPR technology has reduced the toxic RNA that drives Huntington's disease in mice, providing preclinical proof of principle for a new way to treat the fatal neurodegenerative disorder, according to a study published on December 12 in Nature Neuroscience. Read More
Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter